Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed by cells that the company harnesses to carry therapeutic cargo. Late Tuesday, Codiak priced its offering of 5.5 million shares at $15 apiece, the midpoint of its projected $14 to $16 per share … Continue reading “Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin”
Category: New York
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study. The Gossamer … Continue reading “Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma”
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the public to finance its research of potential new treatments for both cancer and infectious disease. In paperwork filed with securities regulators late last week, SQZ set a preliminary $75 million goal … Continue reading “SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D”
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due to safety concerns. The Avenue (NASDAQ: [[ticker:ATXI]]) drug is an intravenous formulation of tramadol, an opioid that first reached the US market 25 years ago in pill form. Now New York-based Avenue is trying to … Continue reading ““Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug”
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them they’ve won the highest honor in their fields. This week, the 2020 Nobel Prize in physiology or medicine was awarded to Harvey Alter, Michael Alton, and Charles Rice, whose research … Continue reading “Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More”
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting
Science is the way out of this pandemic—and scientific breakthroughs are on the ballot on November 3. To help you get ready for Election Day, BIO’s initiative Biotech Votes has resources to help you get registered and get informed. First, make sure you’re registered to vote. Check out this handy form to verify your voter … Continue reading “BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting”
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B
Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for a rare type of heart disease is on track for an FDA submission and is projected to become a blockbuster seller, if approved. According to financial terms announced Monday, Bristol (NYSE: [[ticker:BMY]]) … Continue reading “Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B”
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
Amid the bombast of Tuesday’s presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and efforts to develop a COVID-19 vaccine. In the crosstalk, the president made an unsupported claim that we are weeks away from having vaccines. It’s true that some pharmaceutical companies are already manufacturing their COVID-19 vaccine candidates … Continue reading “Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More”
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume
Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to now resume after patient complications last year led the agency to halt the study for a second time. Cambridge, MA-based Solid Bio (NASDAQ: [[ticker:SLDB]]) said Thursday that it expects dosing of patients in the Phase 1/2 … Continue reading “FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume”
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China
CStone Pharmaceuticals has touted its experimental drug sugemalimab as potentially the best in its class of cancer immunotherapies. Pfizer is placing a bet on that promise by making a $200 million equity investment in CStone for rights to that drug in China. According to deal terms announced late Tuesday, Pfizer (NYSE: [[ticker:PFE]]) is purchasing nearly … Continue reading “Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China”
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug
Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder. On Wednesday, New York-based Ovid (NASDAQ: [[ticker:OVID]]) reported Phase … Continue reading “With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug”
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and revealed $100 million in cumulative financing. Now the company is aiming to raise about that amount in an IPO that will fund clinical development of its drug pipeline. Cambridge, MA-based Praxis … Continue reading “Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs”
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More
In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal. Grail set out with the goal of developing a diagnostic test that detects cancer from the genetic snippets tumors … Continue reading “Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More”
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs
Many drugs work by binding to a protein and blocking it. Technology for eliminating disease-causing proteins altogether remains experimental, but this approach has gained ground in the past year with hundreds of millions of dollars raised and compounds advanced into clinical testing. Monte Rosa is one of the newer companies in this “protein degradation” space … Continue reading “Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs”
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week
The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET. Registration is complimentary and includes access to a networking app with already more than 600 life science contacts. The daily series leads up to the Thursday, Sept. 24 free online National Xconomy Awards … Continue reading “Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week”
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This week, it made its biggest buy yet. The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. Some of those analysts think Gilead might … Continue reading “Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More”
Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series
The Xcelerate Keynote Series has added Moderna CMO Tal Zaks to the expert lineup of speakers set to present next Monday, Sept. 21. As you likely know, Moderna is one of the front-runners in the COVID-19 vaccine race, and we look forward to adding his insight to a packed agenda focused on innovative solutions during … Continue reading “Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series”
Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy
Cell therapy offers another option for addressing the most difficult blood cancer cases, but such treatments, which are engineered from a patient’s own immune cells, don’t yet work on solid tumors. Neogene Therapeutics is developing technology with the potential to bring cell therapies to solid tumors and it now has $110 million to advance its … Continue reading “Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy”
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals
Seattle Genetics is in line to receive $1.72 billion from Merck via a pair of deals, one for a cancer drug that’s still in development and the other for partial rights to a therapy that won FDA approval earlier this year. The larger of the two deals is for the drug still in clinical development, … Continue reading “Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals”
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout
Gilead Sciences is acquiring Immunomedics in a $21 billion deal, the latest in a string of transactions the company has made to bolster its cancer drug portfolio. The acquisition announced Sunday comes five months after Morris Plains, NJ-based Immunomedics won FDA approval for cancer drug sacitizumab govitecan (Trodelvy). The regulatory decision covers triple negative breast … Continue reading “Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout”
Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston
Presented by Xconomy, the online Xcelerate Keynote Series at Biotech Week Boston on Monday, Sept. 21 places a spotlight on life science leaders who are breaking new ground with methods and solutions in R&D, planning, and production that are improving patient outcomes. As the industry navigates uncertainty, the keynote speakers will help drive your business … Continue reading “Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston”
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More
COVID-19 research efforts are often characterized as a race between companies, a description that reflects the urgency to develop a vaccine for the novel coronavirus. The description is not quite right. A race has one winner and public health officials have said we’ll need multiple vaccines to address the global need. Vaccine developers have progressed … Continue reading “Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More”
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
Labor Day is just around the corner and many people are looking forward to a last chance to celebrate the waning days of summer. But ahead of the holiday weekend, biopharmaceutical companies were hard at work closing deals. Food conglomerate Nestlé is delving deeper into pharmaceuticals with its $2.6 billion deal to acquire Aimmune Therapeutics, … Continue reading “Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More”
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25%
[Corrected, 9/2/2020. See below.] Intercept Pharmaceuticals is cutting one-fourth of its workforce, a decision that comes two months after the FDA rejected its drug candidate for the liver disease nonalcoholic steatohepatitis (NASH). Up until the FDA’s rejection of the drug, obeticholic acid (Ocaliva), Intercept (NASDAQ: [[ticker:ICPT]]) had been preparing for a drug launch. In a … Continue reading “Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25%”
Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday
Don’t miss out on savings for this year’s online Xcelerate Keynote Series at Biotech Week Boston – our early bird sale ends this Friday! Speakers include: Jeff Baker – Deputy Director, Office of Biotechnology Products, FDA Michelle McMurry-Heath – President & CEO, BIO John Maraganore – CEO, Alnylam Pharmaceuticals Yvonne Greenstreet – Chief Operating Officer, Alnylam Pharmaceuticals Andrew Plump … Continue reading “Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday”
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More
Among the casualties of the COVID-19 pandemic: the credibility of government agencies entrusted with protecting public health. The FDA this week granted emergency use authorization for convalescent plasma as a treatment for infection by the novel coronavirus. FDA Commissioner Stephen Hahn and Department of Health and Human Services Secretary Alez Azar both misrepresented the magnitude … Continue reading “Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More”
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests
Many of the drugs tested in Alzheimer’s disease so far, and some still in development, aim to block or break up proteins associated with the progression of the memory-robbing disorder. Athira Pharma is taking a different approach—neuron regeneration. And it’s doing so by a tapping a protein first discovered in the liver. Seattle-based Athira has … Continue reading “Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests”
AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial
A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage trial as a potential fix for overactive bladder and urinary incontinence. The FDA in 2013 approved the use of onabotulinumtoxinA (Botox) via injection into the bladder as a treatment for overactive bladder in adults who can’t take or … Continue reading “AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial”
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
Not long ago, having early data about how an experimental drug worked in humans was expected of biotechs considering IPOs. Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector … Continue reading “Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases”
FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines
The FDA has authorized the use of plasma from people who have recovered from infection by the novel coronavirus as a treatment for hospitalized COVID-19 patients, a move widely perceived as influenced by political pressure given the lack of clear evidence of clinical benefit. Treating patients with plasma—the water, salts, and proteins that make up … Continue reading “FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines”
Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More
While business is historically slow in August, this month seems to be bucking the trend, just like so many other unexpected developments in 2020. Perhaps life sciences executives have been less distracted by summer excursions this year in a world in which the COVID-19 pandemic has significantly curtailed travel. This week two pharmaceutical companies announced … Continue reading “Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More”
J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout
[Updated, 7:40 p.m. See below.] Johnson & Johnson is acquiring Momenta Pharmaceuticals in a $6.5 billion deal that brings the pharma giant a slate of experimental autoimmune disease therapies, including a potential blockbuster antibody drug in late-stage development for a rare type of anemia. Momenta (NASDAQ: [[ticker:MNTA]]) develops treatments for diseases driven by autoantibodies—antibodies produced … Continue reading “J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout”
Axovant’s Paul Korner Named Chief Medical Officer of Agile Therapeutics
Agile Therapeutics (NASDAQ: [[ticker:AGRX]]) has appointed Paul Korner to serve as its chief medical officer. He comes to the Princeton, NJ-based company from Axovant Gene Therapies, where he was senior vice president of clinical development & medical affairs. His experience also includes roles at Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Agile is preparing … Continue reading “Axovant’s Paul Korner Named Chief Medical Officer of Agile Therapeutics”
Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy
Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy developed by Dragonfly Therapeutics, a firm that’s already a partner on potential treatments in oncology and other disease areas. New York-based Bristol (NYSE: [[ticker:BMY]]), which inherited a relationship with the biotech when it acquired … Continue reading “Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy”
Advisory Body Backs MesoBlast Therapy for Transplant Complication
An FDA advisory committee Thursday voted 9-1 to recommend that the agency approve a stem cell therapy developed by MesoBlast as a treatment for acute graft-versus-host disease (aGVHD) in children. The panel weighed the need for a new way to address the potentially fatal condition against shortcomings of the clinical trial the Australian biotech conducted … Continue reading “Advisory Body Backs MesoBlast Therapy for Transplant Complication”
CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears
CureVac is playing catch-up to its messenger RNA (mRNA) peers in the race to develop a COVID-19 vaccine, but the company contends its technology could offer dosing advantages, and it now has $213 million in IPO cash to fund the human tests that could support that claim. On Friday, CureVac (NASDAQ: [[ticker:CVAC]]) sold more than … Continue reading “CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears”
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The results are … Continue reading “Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More”
With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor
[Updated 8/13/2020, 3:19 p.m.] Duchenne muscular dystrophy (DMD) patients whose disease is characterized by a particular genetic mutation now have a new treatment option following the FDA’s Wednesday approval of a drug developed by NS Pharma. DMD is a genetic disorder that leaves patients unable to produce dystrophin, a protein key to muscle function. NS … Continue reading “With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor”
Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia
Two California biotechs have teamed up with LianBio, a new company launched earlier this week by hedge fund Perceptive Advisors, as part of deals that expand their reach into China as partners of the fledgling Shanghai-based firm. LianBio is getting the rights to develop and commercialize in Asia certain drugs from the pipelines of Brisbane, … Continue reading “Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia”
F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections
Fungal infections might not immediately come to mind as rare diseases, but growing resistance to older drugs means that patients who develop these infections have limited treatment options. Biotech company F2G aims to give these patients another choice. As the startup looks ahead to late-stage testing of its lead drug candidate, it has raised $60.8 … Continue reading “F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections”
Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political
Pfizer Inc. CEO Albert Bourla said he doesn’t worry about political pressure to bring potentially the first coronavirus vaccine to market, but can’t escape feeling the weight of the world on his shoulders. Bourla’s company is among the leaders in developing a vaccine that could ease the strain of the global pandemic that has caused … Continue reading “Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political”
Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy
Bayer has been building up its women’s health drug pipeline by striking deals and on Tuesday the pharmaceutical giant unveiled its latest one: $425 million up front for KaNDy Therapeutics, a biotech whose experimental menopause drug is projected as a blockbuster seller. KaNDy’s small molecule drug, NT-814, is in development as a treatment for common … Continue reading “Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy”
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home. Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and South Plainfield, NJ-based PTC Therapeutics (NASDAQ: [[ticker:PTCT]]). Regulators OK’d the drug, intended for daily … Continue reading “FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy”
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments. This week saw another major development brought on by industry efforts to adjust to … Continue reading “Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More”
MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer
Robert Zeldin has joined gene therapy developer MeiraGTx (NASDAQ: [[ticker:MGTX]]) as its chief medical officer. Most recently he held the same role at Immunovant (NASDAQ: [[ticker:IMVT]]). Prior Zeldin served as CMO at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]) and at Ablynx. His experience also includes time at Stallergenes, Novartis (NYSE: [[ticker:NVS]]), and Merck, as well as a … Continue reading “MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer”
As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up
Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients to seek ways to manage their health from home. Teladoc (NYSE: [[ticker:TDOC]]) provides “virtual healthcare services” that give patients the ability to visit with a doctor remotely. Most … Continue reading “As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up”
Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch
A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs to change its design and run another clinical trial testing the modified version if it wants the treatment reviewed again. DBV (NASDAQ: [[ticker:DBVT]]), which has its … Continue reading “Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch”
Legend Biotech CEO Xu Resigns, GenScript’s Zhang Named Successor
Yuan Xu, the CEO of Legend Biotech (NASDAQ: [[ticker:LEGN]]) for the past two years, has resigned for “personal reasons,” the company announced Sunday. No other details were given. She has also stepped down from the Somerset, NJ, company’s board of directors. Frank Zhang, chairman of Legend’s board and CEO of GenScript, the biotech’s largest shareholder, … Continue reading “Legend Biotech CEO Xu Resigns, GenScript’s Zhang Named Successor”
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation
Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it’s now looking to tap the public markets to finance tests of the technology in humans. In paperwork submitted to the Securities and Exchange Commission on Friday, Kymera set a $100 million goal for … Continue reading “Kymera Therapeutics Unveils IPO Pitch for Protein Degradation”
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More
The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. If you’ve never heard of Arya (NASDAQ: [[ticker:ARYBU]]), it’s a shell company that Perceptive Advisors … Continue reading “Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More”